Skip to content

Analysts dissect Walgreens-Rite Aid deal

Zacks Investment Research stock strategists Tracey Ryniec and David Bartosiak discussed with Zacks’ Terry Ruffolo the Walgreens Boots Alliance’s proposal to acquire Rite Aid Corp. for $9 per share in cash, and assumption of debt, for a total value of $17.2 billion.

Zacks Investment Research stock strategists Tracey Ryniec and David Bartosiak discussed with Zacks’ Terry Ruffolo the Walgreens Boots Alliance’s proposal to acquire Rite Aid Corp. for $9 per share in cash, and assumption of debt, for a total value of $17.2 billion.

The companies announced the deal late Tuesday, after news reports about an impending agreement surfaced earlier in the day.

Besides looking at the drug store and pharmacy market implications of a Walgreens-Rite Aid combination, the Zacks analysts also assessed the ramifactions for the companies’ stock. Rite Aid shares shot up over 40% after the first reports of a possible deal emerged. WBA’s share price also rose.

However, both stocks have cooled a bit, the analysts noted. Rite Aid shares closed at $7.88 on Thursday, down from $8.06 on Wednesday and $8.67 on Tuesday. On Monday, the day before the deal was announced, Rite Aid shares closed at $6.08.

WBA shares finished at $83.88 on Thursday, down from the closing price of $84.95 on Wednesday and $95.16 on Tuesday. The company’s stock price closed at $89.48 on Monday, prior to the acquisition announcement.

Latest

H-E-B embodies purposefulness

H-E-B embodies purposefulness

During remarks delivered at last month’s FMI Midwinter Executive Conference, Boyan, who is also the association’s chairman, spoke about what motivates the company.

The K-shaped economy’s hidden truths

The K-shaped economy’s hidden truths

New research from the Kearney Consumer Institute uncovers some hidden aspects of the trend, which, of course, has serious implications for both mass market retailers and consumer packaged goods companies.